Computational drug discovery and design integrates advanced computer‐aided methodologies with chemical and biological insights to accelerate the identification and optimisation of therapeutic agents.
Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established constraints. Generative AI turns that on its head. It is an expansive force, ...
Deep Origin, the computational drug discovery company replacing guesswork with prediction in small molecule drug development, today announced the promotion of Natalie Ma, PhD, to Chief Business ...
Hosted on MSN
Chemistry LLM developed for faster drug discovery
Southwest Research Institute scientists and engineers have developed a custom large language model (LLM) to accelerate drug design and discovery. Subscribe to our newsletter for the latest sci-tech ...
Pharmaceutical Technology on MSN
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery
The collaboration builds on Biophytis' ongoing partnership with LynxKite and aligns with Singapore’s research, innovation and enterprise (RIE) 2030 plan.
Under the collaboration, Topos will leverage Dalriada's expertise and infrastructure in protein mass spectrometry and chemoproteomics to support discovery efforts against intrinsically disordered and ...
Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...
PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to ...
TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...
PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the ...
Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...
Computational drug discovery and design embodies the integration of advanced computational methods, machine learning, and cheminformatics to streamline the identification and optimisation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results